Irinotecan, a key chemotherapeutic drug for metastatic colorectal cancer
Published 2015 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Irinotecan, a key chemotherapeutic drug for metastatic colorectal cancer
Authors
Keywords
-
Journal
WORLD JOURNAL OF GASTROENTEROLOGY
Volume 21, Issue 43, Pages 12234
Publisher
Baishideng Publishing Group Inc.
Online
2016-03-12
DOI
10.3748/wjg.v21.i43.12234
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Sex-dependent regulation of hepatic CYP3A by growth hormone: Roles of HNF6, C/EBPα, and RXRα
- (2015) Jie Li et al. BIOCHEMICAL PHARMACOLOGY
- OATP1B1 and tumour OATP1B3 modulate exposure, toxicity and survival after irinotecan-based chemotherapy
- (2015) W A Teft et al. BRITISH JOURNAL OF CANCER
- Functional Gene Variants of CYP3A4
- (2014) A N Werk et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Pharmacogenomics of Human Uridine Diphospho-Glucuronosyltransferases and Clinical Implications
- (2014) C Guillemette et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Dose-Finding and Pharmacokinetic Study to Optimize the Dosing of Irinotecan According to theUGT1A1Genotype of Patients With Cancer
- (2014) Federico Innocenti et al. JOURNAL OF CLINICAL ONCOLOGY
- Irinotecan Pharmacogenetics: A Finished Puzzle?
- (2014) Mitch A. Phelps et al. JOURNAL OF CLINICAL ONCOLOGY
- FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial
- (2014) Volker Heinemann et al. LANCET ONCOLOGY
- Initial Therapy with FOLFOXIRI and Bevacizumab for Metastatic Colorectal Cancer
- (2014) Fotios Loupakis et al. NEW ENGLAND JOURNAL OF MEDICINE
- International Transporter Consortium Commentary on Clinically Important Transporter Polymorphisms
- (2013) K M Giacomini et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Chemotherapy dosing in overweight and obese patients with cancer
- (2013) Gary H. Lyman et al. Nature Reviews Clinical Oncology
- Direct Inhibition and Down-regulation by Uremic Plasma Components of Hepatic Uptake Transporter for SN-38, an Active Metabolite of Irinotecan, in Humans
- (2013) Ken-ichi Fujita et al. PHARMACEUTICAL RESEARCH
- Pharmacogenetics of ABC and SLC transporters in metastatic colorectal cancer patients receiving first-line FOLFIRI treatment
- (2013) Elena De Mattia et al. Pharmacogenetics and Genomics
- Concomitant polypharmacy is associated with irinotecan-related adverse drug reactions in patients with cancer
- (2012) Tetsuya Sasaki et al. International Journal of Clinical Oncology
- Appropriate Chemotherapy Dosing for Obese Adult Patients With Cancer: American Society of Clinical Oncology Clinical Practice Guideline
- (2012) Jennifer J. Griggs et al. JOURNAL OF CLINICAL ONCOLOGY
- Evaluation of Exposure Change of Nonrenally Eliminated Drugs in Patients With Chronic Kidney Disease Using Physiologically Based Pharmacokinetic Modeling and Simulation
- (2012) Ping Zhao et al. JOURNAL OF CLINICAL PHARMACOLOGY
- A genotype-directed phase I–IV dose-finding study of irinotecan in combination with fluorouracil/leucovorin as first-line treatment in advanced colorectal cancer
- (2011) E Marcuello et al. BRITISH JOURNAL OF CANCER
- Health and economic burden of the projected obesity trends in the USA and the UK
- (2011) Y Claire Wang et al. LANCET
- Association of carboxylesterase 1A genotypes with irinotecan pharmacokinetics in Japanese cancer patients
- (2010) Kimie Sai et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- Delayed Elimination of SN-38 in Cancer Patients with Severe Renal Failure
- (2010) K.-i. Fujita et al. DRUG METABOLISM AND DISPOSITION
- Randomized, Phase III Trial of Panitumumab With Infusional Fluorouracil, Leucovorin, and Oxaliplatin (FOLFOX4) Versus FOLFOX4 Alone As First-Line Treatment in Patients With Previously Untreated Metastatic Colorectal Cancer: The PRIME Study
- (2010) Jean-Yves Douillard et al. JOURNAL OF CLINICAL ONCOLOGY
- Interindividual variability in hepatic drug glucuronidation: studies into the role of age, sex, enzyme inducers, and genetic polymorphism using the human liver bank as a model system
- (2009) Michael H. Court DRUG METABOLISM REVIEWS
- Predictive Role of the UGT1A1, UGT1A7, and UGT1A9 Genetic Variants and Their Haplotypes on the Outcome of Metastatic Colorectal Cancer Patients Treated With Fluorouracil, Leucovorin, and Irinotecan
- (2009) Erika Cecchin et al. JOURNAL OF CLINICAL ONCOLOGY
- Comprehensive Pharmacogenetic Analysis of Irinotecan Neutropenia and Pharmacokinetics
- (2009) Federico Innocenti et al. JOURNAL OF CLINICAL ONCOLOGY
- Genotype-Driven Phase I Study of Irinotecan Administered in Combination With Fluorouracil/Leucovorin in Patients With Metastatic Colorectal Cancer
- (2009) Giuseppe Toffoli et al. JOURNAL OF CLINICAL ONCOLOGY
- Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer
- (2009) Eric Van Cutsem et al. NEW ENGLAND JOURNAL OF MEDICINE
- Association of SUMO1 and UBC9 genotypes with tumor response in non-small-cell lung cancer treated with irinotecan-based chemotherapy
- (2009) Ji-Youn Han et al. PHARMACOGENOMICS JOURNAL
- Genetic testing for UGT1A1*28 and *6 in Japanese patients who receive irinotecan chemotherapy
- (2008) Y. Akiyama et al. ANNALS OF ONCOLOGY
- Life-threatening toxicities in a patient with UGT1A1*6/*28 and SLCO1B1*15/*15 genotypes after irinotecan-based chemotherapy
- (2008) Hiroshi Takane et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Renal Function as a Predictor of Irinotecan-induced Neutropenia
- (2008) FA de Jong et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Irinotecan in the treatment of elderly patients with advanced colorectal cancer
- (2008) Javier Sastre et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- Bevacizumab in Combination With Oxaliplatin-Based Chemotherapy As First-Line Therapy in Metastatic Colorectal Cancer: A Randomized Phase III Study
- (2008) Leonard B. Saltz et al. JOURNAL OF CLINICAL ONCOLOGY
- Re: UGT1A1*28 Genotype and Irinotecan-Induced Neutropenia: Dose Matters
- (2008) Wataru Ichikawa et al. JNCI-Journal of the National Cancer Institute
- Integrated pharmacogenetic prediction of irinotecan pharmacokinetics and toxicity in patients with advanced non-small cell lung cancer
- (2008) Ji-Youn Han et al. LUNG CANCER
- Rapid screening of antineoplastic candidates for the human organic anion transporter OATP1B3 substrates using fluorescent probes
- (2007) Hiroaki Yamaguchi et al. CANCER LETTERS
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started